Schizophrenia is a debilitating illness with a lifetime prevalence estimate of 0.6% and
consists of symptoms from the positive, negative, and cognitive domains. Social support …

Schizophrenia is a severe mental disorder characterized by a heterogeneous symptom
profile which comprises a clinical platform for widespread use of polypharmacy even though …

The term polypharmacy was originally coined to refer to problems related to multiple drug
consumption and excessive drug use during the treatment of a disease or disorder. In the …

BackgroundAlthough clozapine is often discontinued, there is a paucity of guidelines and
evidence on treatment options after clozapine discontinuation. Moreover, it is currently …

Background Psychotropic polypharmacy and high-dose prescribing may play a role in
therapy, however, with associated risks. The aim of this study was to describe current …

Schizophrenia is a psychotic disorder that exists at the more extreme end of a spectrum of
diseases, and significantly affects daily functioning. Cardiovascular adverse effects of …

Second-generation antipsychotic metabolism is mainly carried out by the CYP450
superfamily, which is highly polymorphic. Therefore, knowing the influence of the different …

Background Schizophrenia is a serious and debilitating psychiatric disorder that is linked to
marked social and occupational impairment. Despite the vital relevance of medication, non …

Introduction Antipsychotic polypharmacy (APP), defined as the use of more than one
antipsychotic, is common in schizophrenia. However, current guidelines consider that the …

Introduction: Despite treatment with antipsychotic medication, approximately 1/3 of
individuals with schizophrenia will fail to have an adequate response. To treat these …